Capricor Therapeutics Receives Revised Analyst Outlook Following Clinical Milestone

Capricor Therapeutics US14070B3096

Shares of Capricor Therapeutics are undergoing a reassessment by market experts, reflecting a shift in sentiment. The biotech firm’s stock, which closed at $28.31 after a 1.91% decline on Friday, is navigating a period of significant market volatility.

The recent movement in Capricor’s valuation is anchored in promising data from its pivotal HOPE-3 Phase 3 trial. The company’s cell therapy, Deramiocel, designed to treat Duchenne Muscular Dystrophy, successfully met its primary endpoint. Results demonstrated a 54% reduction in disease progression compared to a placebo. A key secondary endpoint, measuring the decline in cardiac function, showed an even more substantial 91% improvement.